Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

NCT00254891 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00254891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2005
Completion date
July 31, 2008
Enrollment
828 (actual)
Sites
191

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung